Apeloa Pharmaceutical Co., Ltd | Apeloa Pharmaceutical Co., Ltd.

 

Apeloa - Science-Driven Solutions with Global Scale

Apeloa CDMO is the contract discovery, development and manufacturing division of Apeloa Pharmaceutical Co., Ltd., a subsidiary of the Hengdian Group, one of China’s largest private enterprises. With over 30 years of industry experience, Apeloa stands as a trusted partner to global pharma and biotech companies, offering full-spectrum solutions from early-stage development to commercial-scale GMP production.

Strategically positioned across three continents, our state-of-the-art facilities and multidisciplinary teams deliver high-quality APIs, Intermediates, and Registered Starting Materials (RSMs)—all backed by robust regulatory compliance, innovation in process design, and best-in-class customer service.

 

Core Capabilities

• API Process Development & Manufacturing
• High-Potency API (HPAPI) – OEB4 & OEB5
• Flow Chemistry
• ADC Payloads & Linker Development
• Synthetic Peptides
• monodisperse PEGs (GMP, commercial scale)
• Ionizable lipids (for LNPs – CLs, ILs, PEG-Lipid)
• PROTAC/TPD Molecule Manufacturing

 

• Medicinal Chemistry (Med. Chem)
• Full-Time Equivalent (FTE) Research Support
• Analytical Development & Quality Control
• Global Regulatory Affairs & CMC Filing
• Formulation Development & Manufacturing

 

Global Footprint

Corporate Presence: 

Headquarters: Hengdian, China
Frankfurt am Main, Germany | Boston, USA | Tokyo, Japan

R&D Centers of Innovation 

Location	Facility Size	Scientists	Focus Areas
Boston, USA	16,000 sq ft	40+	Tech development, lead optimization, screening, tox batches
Shanghai, China	68,000 sq ft	300+	High-throughput screening, process development, CMC
Hengdian, China	88,000 sq ft	250+	Tech transfer, process optimization, CMC

 

Manufacturing Infrastructure

• 8 globally manufacturing sites

              Certifications: cGMP, ISO9001, ISO14001, OSHAS18001, IPMS

              Full regulatory reach: US FDA, EMA, PMDA, NMPA, KFDA, and more

•  Production Capacity

              Chemical Synthesis:

                 - Total area: 11,000 m³

                 - Reactors: 50 L - 45,000 L

                 - Output API: 4,000 MT/year

                 - Intermediates: 38,000 MT/year

              Bio-Production:

                - Total area: 6,570 m³

                - Reactors: 50 L - 120,000 L

                - Output API: 2,000 MT/year

                - Intermediates: 2,000 MT/year

              HPAPI:

                - Total reactor volume: 75 m³ (clinical & commercial scale)

                - OEB 4 (PDE = 10 - 100 µg/day)

                - OEB 5 (PDE < 10 µg/day)

              Multifunctional API Workshops: 658 m³ for parallel production

 

Why Choose Apeloa CDMO?

Reliable. Responsive. Globally Certified – Apeloa CDMO delivers flexible, science-led manufacturing with a global footprint. Whether you’re scaling a molecule or accelerating commercialization, we’re the partner that moves with your vision.